drugset
drugset / Trial / NCT00288951

Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00288951 ↗

Phase 3 Completed 690 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension

Timeline

Start
2004-10
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 0.004 % —

Indications

ocular hypertension open-angle glaucoma